Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

(MENAFN- GlobeNewsWire - Nasdaq) WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc.
(NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel
portfolio of oncolytic immunotherapies, today announced the grant of inducement equity awards to Emily Hill, the Company's newly appointed Chief Financial Officer.

The inducement awards consist of a non-qualified stock option to purchase 125,000 shares of the Company's common stock and restricted stock units representing 83,330 shares of the Company's common stock. The option has an exercise price of $18.00 per share, which is equal to the closing price of the Company's common stock on the date of grant. The option has a 10-year term and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the remainder vesting monthly for three years thereafter. The restricted stock units vest in approximately four equal annual installments beginning on August 15, 2024.

The inducement awards were approved by the compensation committee of the Company's board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4). While the inducement awards were granted outside of the Company's 2018 Equity Incentive Plan, the awards will have terms and conditions consistent with those set forth under the plan.

About Replimune
Replimune Group, Inc.
, headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment
by pioneering the development of novel
oncolytic immunotherapies. Replimune's proprietary RPx platform
is based on a potent HSV-1 backbone with added payloads intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform
is intended to provide a unique dual local and systemic mechanism of action consisting of direct selective virus- media
ted killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. This MOA is expected to be synergistic with most established and experimental cancer treatment
modalities, and, with an attractive safety profile the RPx platform
has the versatility to be developed alone or combined with a variety of other treatment
options. For more information, please visit .

Investor Inquiries
Chris Brinzey
Westwicke, an ICR Company

Media Inquiries
Arleen Goldenberg


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.